1. LA Dawson and JM Watson. Vilazodone: a 5-HT1A receptor agonist/serotonin transporter inhibitor for the treatment of affective disorders. CNS Neurosci Ther 2009; 15:107.

2. MH Trivedi et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006; 354:1243.

3. A Khan. Vilazodone, a novel dual-acting serotonergic antidepressant for managing major depression. Expert Opin Investig Drugs 2009; 18:1753.

4. K Rickels et al. Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2009; 70:326.

5. MJ Taylor et al. Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis. Arch Gen Psychiatry 2006; 63:1217.

6. DS Robinson et al. A 1-year open-label study assessing the safety and tolerability of vilazodone in patients with major depressive disorder. Paper presented at the 163rd annual meeting of the American Psychiatric Association, New Orleans, LA, May 2010.

7. CD Chambers et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006; 354:579.

8. RJ Baldessarini et al. Illness risk following rapid versus gradual discontinuation of antidepressants. Am J Psychiatry 2010; 167:934.